Form 4: Viridian Therapeutics' Chief Medical Officer Granted Stock Options
SEC Form 4 Filing
Radhika Tripuraneni, Chief Medical Officer of Viridian Therapeutics, was granted stock options to purchase 310,700 shares of common stock.
Summary
- Radhika Tripuraneni, the Chief Medical Officer of Viridian Therapeutics, Inc., was granted stock options on March 10, 2025.
- The options allow her to purchase 310,700 shares of Viridian Therapeutics' common stock at an exercise price of $15.58 per share.
- The options vest as to 25% on March 10, 2026, and then in equal monthly installments over the following 36 months, contingent upon her continued service to the company.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The vesting schedule suggests a long-term commitment.
Positives
- The granting of stock options to the Chief Medical Officer aligns her interests with those of the shareholders.
- The vesting schedule incentivizes continued service and commitment to the company's success.
Future Outlook
The vesting schedule suggests a commitment to long-term value creation and retention of key personnel.
Industry Context
Granting stock options to key executives is a common practice in the biotechnology industry to incentivize performance and align management's interests with those of shareholders. This is a standard compensation practice to attract and retain talent.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry.
- Companies like Amgen, Regeneron, and Biogen routinely use stock options to incentivize their leadership teams.
- The vesting schedule of 25% after one year followed by monthly vesting over three years is a fairly standard practice.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the Chief Medical Officer to drive company success.
- Employees may see this as a positive sign of investment in leadership and the company's future.
Key Dates
| Date | Description |
|---|---|
| 03/10/2025 | Date of the stock option grant. |
| 03/10/2026 | Date when 25% of the stock options begin to vest. |
| 03/10/2035 | Expiration date of the stock options. |
| 03/12/2025 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.